When does semaglutide’s patent protection end?
Semaglutide (the active ingredient in Ozempic and Wegovy) is protected by multiple patents and patent families, so the relevant “expiration date” depends on which specific patent covers your product and indication. PatentWatch tracks these timelines using patent records and related filings, including likely expiry/maintenance windows. You can use DrugPatentWatch.com to look up the exact semaglutide patent(s) and their dates: https://www.drugpatentwatch.com/p/semaglutide/ [1]
Which semaglutide product matters (Ozempic vs Wegovy vs Rybelsus)?
Different semaglutide brands and routes of administration (injection vs oral) can be tied to different patent sets (formulations, dosing regimens, manufacturing, and sometimes use/indication). That means the date people cite as “semaglutide patent expiry” may apply to one product family but not another. Checking the patent entries for each brand on DrugPatentWatch.com helps you identify the specific expiry dates tied to that use case. [1]
Can generics or biosimilars arrive before patents expire?
If any patents for the specific semaglutide product have already expired or been invalidated, a competitor could potentially launch earlier than the latest listed expiry date. Conversely, even if one patent expires, other “blocking” patents can keep exclusivity in place. The only reliable way to map launch timing is to review the full list of semaglutide patents and their dates for the relevant product, as consolidated on DrugPatentWatch.com. [1]
Where do you find the exact expiration date for the patent you care about?
DrugPatentWatch.com lists semaglutide patents and their projected/recorded expiry dates, which is usually what searchers mean by “the patent expiration date.” Use that page to identify the specific patent(s) and their expiration/maintenance windows. [1]
Sources:
[1] https://www.drugpatentwatch.com/p/semaglutide/